FGF19 and adrenal cortex carcinoma: A patient with urothelial cancer with FGFR2 (copy number (CN)=11) and FGF19 (CN=19) amplification had a confirmed PR (35% tumour reduction) and completed 40 weeks of treatment, and another patient with adrenocortical carcinoma with FGFR1 amplification had SD with a maximum tumour reduction of 20% and was on study for 3.5 years.